BioSpace
Episodes
Money talk: Salary trends and raises
21 Mar 2024
Contributed by Lukas
This week, we're talking money! Following the release of BioSpace's 2024 Salary Report, we discuss salary trends and how they are impacting th...
Historic approval for MASH, CAR-Ts in the spotlight
20 Mar 2024
Contributed by Lukas
Phew, what a week! One of the most anticipated FDA decisions of the year dropped last week when the regulator approved Madrigal’s Rezdiffra as the f...
The unintended consequences of small molecules
14 Mar 2024
Contributed by Lukas
Continuing on from our previous episode "The gap is where the pain is", this episode focuses on a healthy discussion regarding the IRA, part...
The skinny on weight loss, donanemab and the State of the Union
13 Mar 2024
Contributed by Lukas
The weight loss market is the gift that keeps on giving—at least for Novo Nordisk—as Wegovy continues to demonstrate its prowess with label expans...
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now
06 Mar 2024
Contributed by Lukas
These days you can hardly move without figuratively bumping into antibody-drug conjugates (ADCs). This week we discuss Pfizer's strategic prioriti...
The gap is where the pain is: Drug pricing and patient costs
29 Feb 2024
Contributed by Lukas
When it comes to drug pricing, there have been (and are) bad actors in the industry, but the conversation usually ends there. Five KOLs from different...
Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars
28 Feb 2024
Contributed by Lukas
This week Lori, Greg and Tyler discuss AbbVie: how longtime CEO Richard Gonzalez navigated Humira's LOE, his victorious retirement announcement, a...
Iovance wins with Amtagvi and the ADC train chugs on
21 Feb 2024
Contributed by Lukas
This week Lori, Greg and Tyler discuss the Accelerated Approval of Amtagvi, the first one-time cell therapy for solid tumors and the first TIL therap...
Eyes on the prize: Novo buys Catalent
14 Feb 2024
Contributed by Lukas
This week, Greg, Heather and Tyler discuss reaction to Novo Nordisk's purchase of Catalent and speculate on what that means for existing manufactu...
Balancing act: Patient access and innovation
07 Feb 2024
Contributed by Lukas
This week Lori, Greg and Tyler discuss drug pricing reforms. CMS sent offers to manufacturers of the 10 drugs that have been selected for Medicare pri...
Keep calm and CAR-T on?
31 Jan 2024
Contributed by Lukas
Almost 30,000 patients have now been treated with CAR-T cell therapies since it was the first approval in 2017. In November 2023, the FDA launched a p...
What can biopharma expect from the job market?
25 Jan 2024
Contributed by Lukas
Following a challenging year of layoffs and limited funding, Chantal Dresner, VP of Marketing at BioSpace, discusses the findings of our most recent E...
Grab an umbrella, it's raining IPOs!
24 Jan 2024
Contributed by Lukas
The first surge of IPO activity this year sees Alto Neuroscience, ArriVent Biopharma, CG Oncology, Kyverna Therapeutics and Metagenomi making announce...
Optimistic, but for how long? Our big takeaways from #JPM2024
17 Jan 2024
Contributed by Lukas
The team comes together to discuss the dominant themes of what was an incredibly busy week of events in San Francisco. There was an air of hope and o...
On the ground at #JPM2024 - Day 3 highlights
10 Jan 2024
Contributed by Lukas
We're still in San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day three: disruptive...
On the ground at #JPM2024 - Day 2 highlights
10 Jan 2024
Contributed by Lukas
Once again we're recording from San Francisco covering the JP Morgan Healthcare Conference and Biotech Showcase, bringing you key themes from day ...
On the ground at #JPM2024 - Day 1 highlights
08 Jan 2024
Contributed by Lukas
Hello from San Francisco! BioSpace is reporting from #JPM2024 bringing you key takeaways and highlights from day one. Join Lori, Greg and Tyler as the...
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics
04 Jan 2024
Contributed by Lukas
The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become mo...
The top life sciences startups to watch this year
03 Jan 2024
Contributed by Lukas
Welcome to 2024! This week we're discussing BioSpace's tenth annual list of the hottest new life sciences companies in the U.S. NextGen Clas...
What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital
21 Dec 2023
Contributed by Lukas
How can startup leaders support long-term sustainable growth and investment? BioSpace’s Lori Ellis speaks with venture capital guests Ansbert Gadick...
Every move you make: Biopharma industry under heavy scrutiny
20 Dec 2023
Contributed by Lukas
Biden administration flexes regulatory muscles, putting pressure on the biopharma industry over ‘price gouging’ and invoking march-in rights; mean...
What VCs really think of the market right now with MPM Capital, Endeavor Venture Fund and Two Bear Capital
14 Dec 2023
Contributed by Lukas
What needs to happen for funding in biopharma to bounce back? BioSpace’s Lori Ellis discusses the macroeconomic environment and biopharma funding o...
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
13 Dec 2023
Contributed by Lukas
That was Week with a capital W. Two major FDA approvals for sickle cell came through on Friday - Casgevy, the first-ever CRISPR-based gene editing the...
Fast and furious evolution: How to ensure AI is catalyst for positive societal change with Microsoft and IQVIA
12 Dec 2023
Contributed by Lukas
This is the second part of our discussion on the evolution of artificial intelligence and its impact on life sciences with guests from Microsoft and I...
Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA
07 Dec 2023
Contributed by Lukas
Over the last year, the reaction to generative AI has changed - and so have behaviors. People are integrating AI to become more productive and it is h...
GLP-1 and ADC rollercoasters pick up speed
06 Dec 2023
Contributed by Lukas
The weight loss market sees more ups and downs - Altimmune joins the fray and sees a stock jump while Pfizer experiences setbacks; and European Medici...
Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior
05 Dec 2023
Contributed by Lukas
Patient behavior has always had an influence on clinical trials - so how do we contend with missing and/or irregular data now that it is feeding AI mo...
Artificial Intelligence, Part 2: Human Interaction, Liability, and Patient Safety
30 Nov 2023
Contributed by Lukas
The breadth of AI in healthcare applications is broad. How much human oversight is necessary or preferred when leveraging AI in the interest of patien...
Deals, Dupixent and GLP-1 drug shortages
29 Nov 2023
Contributed by Lukas
This week we talk struggles with GLP-1 drug shortages and what that might mean for Novo/Lilly competitors; Regeneron and Sanofi positive results for ...
First ever CRISPR gene therapy approval: What happens next?
21 Nov 2023
Contributed by Lukas
Last Thursday, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved CRISPR/Cas9 gene-edited therapy exagamglogene autote...
Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure
16 Nov 2023
Contributed by Lukas
This is part one of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Topics explored are ROI, human bia...
Zepbound vs Wegovy: A two horse race
15 Nov 2023
Contributed by Lukas
Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegov...
Q3 earnings recap: Winners, losers & surprises
08 Nov 2023
Contributed by Lukas
This week (our inaugural episode!) BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the good, the bad and the ugly of biopharma'...